Prokinetics: the role in the therapy of a patient with GERD
DOI: 10.32364/2587-6821-2023-7-5-6
M.A. Livzan1, D.S. Bordin2–4, O.V. Gaus1, M.A. Lisovsky1
1Omsk State Medical University, Omsk, Russian Federation
2A.S. Loginov Moscow Clinical Research Center, Moscow, Russian Federation
3A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
4Tver State Medical University, Tver, Russian Federation
One of the most common pathologies in the structure of digestive diseases is gastroesophageal reflux disease (GERD), which is associated with low life quality of patients, while in insufficient disease control — with an increased risk of Barrett's esophagus and, as a consequence, adenocarcinoma. In accordance with the relevant consensus papers, in particular, the Lyon Consensus, a key factor in the GERD pathogenesis is a persistent disorder of the upper digestive tract motility with the formation of pathological gastric reflux (in some cases, duodenum) contents into the esophagus, which determines the expediency of including prokinetics in the treatment regimen of the disease. This article provides information about the main risk factors and mechanisms of the pathological reflux in GERD, the frequency and duration of which determine the risk and progression of the disease. Special attention is paid to the modern methods for the correction of esophageal and gastric motor disorders, including the role of prokinetics in the patient's therapy.
Keywords: prokinetics, gastroesophageal reflux disease, functional dyspepsia, itopride hydrochloride.
For citation: Livzan M.A., Bordin D.S., Gaus O.V., Lisovsky M.A. Prokinetics: the role in the therapy of a patient with GERD. Russian Medical Inquiry. 2023;7(5):283–291 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-6.
About the authors:
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy and Gastroenterology, rector, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Olga V. Gaus — C. Sc. (Med.), Assistant Professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Dmitry S. Bordin — Dr. Sc. (Med.), Head of the Department of Pathology of the Pancreas, Biliary Tract and Upper Digestive Tract, A.S. Loginov Moscow Clinical Research Center; 86, bldg. 6, Entuziastov Road, Moscow, 111123, Russian Federation; Professor of the Department of Propaedeutics of Internal Medicine and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry; 20/1, bldg. 1, Delegatskaya str., Moscow, 127473, Russian Federation; Professor of the Department of General Medical Practice and Family Medicine, Tver State Medical University; 4, Sovetskaya Str., Tver, 170100, Russian Federation; ORCID iD 0000-0003-2815-3992.
Maxim M. Lisovskiy — resident of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9674-0545.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 15.03.2023.
Revised 05.04.2023.
Accepted 26.04.2023.
References
1. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97. [Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Refl ux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97 (in Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-70-97.
2. Eusebi L.H., Ratnakumaran R., Yuan Y. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. DOI: 10.1136/ gutjnl-2016-313589.
3. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Up- date on the epidemiology of gastro-oesophageal reflux dis- ease: a systematic review. Gut. 2014;63(6):871–880. DOI: 10.1136/gutjnl-2012-304269.
4. Savarino E., Marabotto E., Bodini G. et al. Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2017;63(3):175–183. DOI: 10.23736/ S1121-421X.17.02383-2.
5. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Результаты Многоцентрового исследования «Эпидемиология Гастроэзофагеальной РЕфлюксной болезни в России» (МЭГРЕ). Терапевтический архив. 2011;83(1):45–50. [Lazebnik L.B., Masharova A.A., Bordin D.S. et al. Results of a multicentre study "Epidemiology of Gastroesophageal Reflux Disease in Russia" (MEGRE). Terapevticheskiy arkhiv. 2011;83(1):45–50 (in Russ.)].
6. Bor S., Lazebnik L.B., Kitapcioglu G. et al. Prevalence of gastroesophageal reflux disease in Moscow. Dis Esophagus. 2016;29(2):159–165. DOI: 10.1111/dote.12310.
7. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Пищевод Барретта. Клинические рекомендации Российской гастроэнтерологической ассоциации. 2014. (Электронный ресурс.) URL: https://www.gastroscan.ru/literature/authors/7752 (дата обращения: 21.02.2023). [Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Barrett's esophagus. Clinical recommendations of the Russian gastroenterological association. 2014. (Electronic resource.) URL: https://www.gastroscan.ru/literature/authors/7752 (access date: 21.02.2023) (in Russ)].
8. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа; 2019. [Maev I.V., Busarova G.A., Andreev D.N. Diseases of the esophagus. M.: GEOTAR-Media, 2019 (in Russ.)].
9. Маев И.В., Самсонов А.А., Белый П.А., Лебедева Е.Г. Гастроэзофагеальная рефлюксная болезнь — лидер кислотозависимой патологии верхних отделов желудочно-кишечного тракта. Consilium Medicum. Гастроэнтерология. 2012;(1):18–24. [Maev I.V., Samsonov A.A., Belyi P.A., Lebedeva E.G. Gastroesophageal reflux disease is the leading acid-dependent pathology of the upper gastrointestinal tract. Consilium Medicum. Gastroenterology. 2012;(1):18–24 (in Russ.)].
10. Cook M.B., Wild C.P., Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050–1061. DOI: 10.1093/aje/kwi325.
11. Thukkani N., Sonnenberg A. The influence of environmental risk factors in hospitalization for gastro-oesophageal reflux disease-related diagnoses in the United States. Aliment Pharmacol Ther. 2010;31(8):852–861. DOI: 10.1111/j.1365-2036.2010.04245.x.
12. Sonnenberg A., Massey B.T., Jacobsen S.J. Hospital discharges resulting from esophagitis among Medicare beneficiaries. Dig Dis Sci. 1994;39(1):183–188. DOI: 10.1007/BF02090080.
13. Richter J.E., Rubenstein J.H. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154(2):267–276. DOI: 10.1053/j.gastro.2017.07.045.
14. Nam S.Y., Choi I.J., Ryu K.H. et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology. 2010;139(6):1902–1911.e2. DOI: 10.1053/j.gastro.2010.08.019.
15. Singh S., Sharma A.N., Murad M.H. et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399–1412.e7. DOI: 10.1016/j.cgh.2013.05.009.
16. Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник Казанской медицинской школы. 2014;1(4):44–48. [Livzan M.A., Kolbina M.V., Matoshina I.V. Adipose tissue hormones and non-alcoholic fatty liver disease in metabolic syndrome. Kazan medical school diary. 2014;1(4):44–48 (in Russ.)].
17. Abdelkader N.A., Montasser I.F., Bioumy E.E., Saad W.E. Impact of anthropometric measures and serum leptin on severity of gastroesophageal reflux disease. Dis Esophagus. 2015;28(7):691–698. DOI: 10.1111/dote.12271.
18. Nelsen E.M., Kirihara Y., Takahashi N. et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2012;10(7):728–e762. DOI: 10.1016/j.cgh.2012.03.007.
19. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Киселев И.Е. Особенности течения гастроэзофагеальной рефлюксной болезни, ассоциированной с ожирением и избыточной массой тела. Терапевтический архив. 2016;88(2):21–27. [Livzan M.A., Lapteva I., Krolevets T.S., Kiselev I. Specific features of gastroesophageal reflux disease associated with obesity and overweight. Terapevticheskii arkhiv. 2016;88(2):21–27 (in Russ.)]. DOI: 10.17116/terarkh201688221-27.
20. Маев И.В., Юренев Г.Л. Фенотип ожирения и гастроэзофагеальной рефлюксной болезни в контексте коморбидности у больных с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2019;91(2):126–133. [Maev I.V., Yurenev G.L., Mironova E.M., Yureneva-Thorzhevskaya T.V. Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases. Terapevticheskiy arkhiv. 2019;91(2):126–133 (in Russ.)]. DOI: 10.26442/00403660.2019.02.000099.
21. Гаус О.В., Ахмедов В.А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал. 2015;1(124):132–137. [Gaus O.V., Akhmedov V.A. Effect of metabolic syndrome on the state of the liver parenchyma and biliary system in patients with cholelithiasis. Ural medical journal. 2015;1(124):132–137 (in Russ.)].
22. Mikolasevic I., Poropat G., Filipec Kanizaj T. et al. Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. Can J Gastroenterol Hepatol. 2021;2021:6670065. DOI: 10.1155/2021/6670065.
23. Wijarnpreecha K., Panjawatanan P., Thongprayoon C. et al. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: a meta-analysis. Saudi Journal of Gastroenterology. 2017;23(6):311–317. DOI: 10.4103/sjg.sjg_161_17.
24. Hung W.-C., Wu J.-S., Yang Y.-C. et al. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis. European Journal of Clinical Investigation. 2014;44(12):1143–1149. DOI: 10.1111/eci.12348.
25. Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2013;11(3):125–129. [Gaus O.V., Akhmedov V.A. Clinical, biochemical and immunological features of cholelithiasis associated with metabolic syndrome. Bulletin of the Novosibirsk State University. Series: Biology, clinical medicine. 2013;11(3):125–129 (in Russ.)].
26. Khan A., Kim A., Sanossian C., Francois F. Impact of obesity treatment on gastroesophageal reflux disease. World J Gastroenterol. 2016;22(4):1627–1638. DOI: 10.3748/wjg.v22.i4.1627.
27. Di Ciaula A., Molina-Molina E., Bonfrate L. et al. Gastrointestinal defects in gallstone and cholecystectomized patients. Eur J Clin Invest. 2019;49(3):e13066. DOI: 10.1111/eci.13066.
28. Кайбышева В.О., Трухманов А.С., Сторонова О.А. и др. Морфофункциональные изменения пищевода при ГЭРБ в зависимости от характера рефлюктата. Клинические перспективы гастроэнтерологии, гепатологии. 2014;5:28–36. [Kaybysheva V.O., Trukhmanov A.S., Storonova О.А. et al. Morphofunctional changes of the esophagus at GERD in relation to refluxate nature. Klinicheskiye perspektivy gastroenterologii, gepatologii. 2014;5:28–36 (in Russ.)].
29. Fass O.Z., Mashimo H. The Effect of Bariatric Surgery and Endoscopic Procedures on Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(1):35–45. DOI: 10.5056/jnm20169.
30. Fox M., Barr C., Nolan S. et al. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5(4):439–444. DOI: 10.1016/j.cgh.2006.12.013.
31. Kahrilas P.J. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4–S19. DOI: 10.3949/ccjm.70.suppl_5.s4.
32. Savarino V., Marabotto E., Zentilin P. et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol. 2020;13(4):437–449. DOI: 10.1080/17512433.2020.1752664.
33. Pouderoux P., Verdier E., Kahrilas P.J. Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. Am J Physiol Gastrointest Liver Physiol. 2003;284(2):G242-G247. DOI: 10.1152/ajpgi.00301.2002.
34. Бордин Д.С. «Кислотный карман» как патогенетическая основа и терапевтическая мишень при гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2014;2:76–81. [Bordin D.S. "Acid pocket" as a pathogenetic basis and therapeutic target for gastroesophageal reflux disease. Terapevticheskii arkhiv. 2014;2:76–81. (in Russ.)].
35. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;21(4):4–13. [Kaibysheva V.O., Trukhmanov A.S., Ivashkin V.T. Gastroesophageal reflux disease resistant to proton pump inhibitor therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(4):4–13 (in Russ.)].
36. Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16(2):148–156. DOI: 10.5056/jnm.2010.16.2.148.
37. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1943. DOI: 10.1111/j.1572-0241.2006.00630.x.
38. Бордин Д.С., Никольская К.А., Бакулин И.Г. и др. Система поддержки принятия врачебных решений. Гастроэнтерология: Клинические протоколы лечения. М.: ГБУ «НИИОЗММ ДЗМ»; 2021. [Bordin D.S., Nikolskaya K.A., Bakulin I.G. et al. Medical decision support system. Gastroenterology: Clinical treatment protocols. M.: "NIIOZMM"; 2021 (in Russ.)].
39. Алексеенко С.А., Багдасарян А.А., Бакулин И.Г. и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Пособие для врачей-терапевтов. Под ред. О.М. Драпкиной. М.: Видокс; 2019. [Alekseyenko S.A., Bagdasaryan A.A., Bakulin I.G., et al. Brief algorithms for managing patients at the stage of providing primary health care. A guide for general practitioners. Drapkina O.M., ed. M.: Vidoks; 2019 (in Russ.)].
40. Gyawali C.P., Kahrilas P.J., Savarino E. et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351–1362. DOI: 10.1136/gutjnl-2017-314722.
41. Yadlapati R., Gyawali C.P., Pandolfino J.E. CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984–994.e1. DOI: 10.1016/j.cgh.2022.01.025.
42. Bischoff S.C., Barazzoni R., Busetto L. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases — Joint ESPEN/UEG guideline. Clin Nutr. 2022;41(10):2364–2405. DOI: 10.1016/j.clnu.2022.07.003.
43. Mathus-Vliegen E.M., Tygat G.N. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–1252. DOI: 10.1080/003655202761020498.
44. Mathus-Vliegen E.M., van Weeren M., van Eerten P.V. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68(2-3):161–168. DOI: 10.1159/000075525.
45. Шептулин А.А., Курбатова А.А., Баранов С.А. Современные возможности применения прокинетиков в лечении больных с гастроэзофагеальной рефлюксной болезнью. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):71–77. DOI: 10.22416/1382-4376-2018-28-1-71-77. [Sheptulin A.A., Kurbatova A.A., Baranov S.A. Modern options of prokinetics in gastroesophageal reflux disease treatment. Ross z gastroenterol gepatol koloproktol. 2018;28(1):71–77 (in Russ.)]. DOI: 10.22416/1382-4376-2018-28-1-71-77.
46. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747–757,e350. DOI: 10.1111/j.1365-2982.2012.01888.x.
47. Jung D.H., Huh C.W., Lee S.K. et al. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):165–175. DOI: 10.5056/jnm20161.
48. Ezzat W.F., Fawaz S.A., Fathey H., El Demerdash A. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease: prospective study. J Otolaryngol Head Neck Surg. 2011;40(4):350–356.
49. Ливзан М.А., Осипенко М.Ф. Синдром перекреста функциональных заболеваний пищеварительного тракта. РМЖ. 2012;15:768. [Livzan M.A., Osipenko M.F. Syndrome of cross functional diseases of the digestive tract. RMJ. 2012;15:768 (in Russ.)].
50. Sanaka M., Yamamoto T., Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–2440. DOI: 10.1007/s10620-009-1076-x.
51. Kountouras J., Chatzopoulos D., Zavos C. et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49(43):193–197.
52. Chun B.J., Lee D.S. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol. 2013;270(4):1385–1390. DOI: 10.1007/s00405-012-2341-8.
53. Ren L.H., Chen W.X., Qian L.J. et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412–2419. DOI: 10.3748/wjg.v20.i9.2412.
54. Ndraha S. Combination of PPI with a prokinetic drug in gastroesophageal reflux disease. Acta Med Indones. 2011;43(4):233–236.
55. Miyamoto M., Haruma K., Takeuchi K., Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23(5):746–751. DOI: 10.1111/j.1440-1746.2007.05218.x.
56. Hunt R., Armstrong D., Katelaris P. et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467–478. DOI: 10.1097/MCG.0000000000000854.
57. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H. et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. DOI: 10.14309/ajg.0000000000001538.
58. Iwakiri K., Fujiwara Y., Manabe N. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–285. DOI: 10.1007/s00535-022-01861-z.
59. Jung H.K., Tae C.H., Song K.H. et al. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(4):453–481. DOI: 10.5056/jnm21077.
60. Gastrooesophageal reflux disease in children and young people: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019.
61. Camilleri M., Atieh J. New Developments in Prokinetic Therapy for Gastric Motility Disorders. Front Pharmacol. 2021;12:711500. DOI: 10.3389/fphar.2021.711500.
62. Goelen N., Jones M., Huang I.H. et al. Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence. United European Gastroenterol J. 2023;11(2):146–162. DOI: 10.1002/ueg2.12362.
63. DiPalma J.R. Metoclopramide: a dopamine receptor antagonist. Am Fam Physician. 1990;41(3):919–924.
64. Bor S., Demir M., Ozdemir O., Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018;6(9):1331–1346. DOI: 10.1177/2050640618799153.
65. Ray W.A., Murray K.T., Meredith S. et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–1096. DOI: 10.1056/NEJMoa040582.
66. Маев И.В., Бордин Д.С., Андреев Д.Н. Тактика врача-гастроэнтеролога: практическое руководство. Под ред. И.В. Маева. М.: ГЭОТАР-Медиа; 2021. [Maev I.V., Bordin D.S., Andreev D.N. Tactics of a gastroenterologist: a practical guide. Maev I.V., ed. Moscow: GEOTAR-Media; 2021 (in Russ.)].
67. Kim Y.S., Kim T.H., Choi C.S. et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol. 2005;11(27):4210–4214. DOI: 10.3748/wjg.v11.i27.4210.
68. Минушкин О.Н., Лощинина Ю.Н. Эффективность применения препарата Ганатон в лечении больных ГЭРБ. Эффективная фармакотерапия в гастроэнтерологии. 2008;3:20–24. [Minushkin O.N., Loschinina Yu.N. Efficacy of Ganaton in GERD therapy. Effective Drug Therapy in Gastroenterology. 2008;3:20–24 (in Russ.)].
69. Takeda N., Takemura M., Kanemitsu Y. et al. Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation. Journal of Asthma. 2019;15:1–9. DOI: 10.1080/02770903.2019.1641204.
70. Huang X., Lv B., Zhang S., Fan Y.H., Meng L.N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371–7377. DOI: 10.3748/wjg.v18.i48.7371.
61. Moayyedi P., Soo S., Deeks J. et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. DOI: 10.1002/14651858.CD001960.pub3.
72. Pittayanon R., Yuan Y., Bollegala N.P. et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233–243. DOI: 10.1038/s41395-018-0258-6.
73. Abid S., Jafri W., Zaman M.U. et al. Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia. World J Gastrointest Pharmacol Ther. 2017;8(1):74–80. DOI: 10.4292/wjgpt.v8.i1.74.
74. Holtmann G., Talley N.J., Liebregts T. et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832–840. DOI: 10.1056/NEJMoa052639.
2. Eusebi L.H., Ratnakumaran R., Yuan Y. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. DOI: 10.1136/ gutjnl-2016-313589.
3. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Up- date on the epidemiology of gastro-oesophageal reflux dis- ease: a systematic review. Gut. 2014;63(6):871–880. DOI: 10.1136/gutjnl-2012-304269.
4. Savarino E., Marabotto E., Bodini G. et al. Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. 2017;63(3):175–183. DOI: 10.23736/ S1121-421X.17.02383-2.
5. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Результаты Многоцентрового исследования «Эпидемиология Гастроэзофагеальной РЕфлюксной болезни в России» (МЭГРЕ). Терапевтический архив. 2011;83(1):45–50. [Lazebnik L.B., Masharova A.A., Bordin D.S. et al. Results of a multicentre study "Epidemiology of Gastroesophageal Reflux Disease in Russia" (MEGRE). Terapevticheskiy arkhiv. 2011;83(1):45–50 (in Russ.)].
6. Bor S., Lazebnik L.B., Kitapcioglu G. et al. Prevalence of gastroesophageal reflux disease in Moscow. Dis Esophagus. 2016;29(2):159–165. DOI: 10.1111/dote.12310.
7. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Пищевод Барретта. Клинические рекомендации Российской гастроэнтерологической ассоциации. 2014. (Электронный ресурс.) URL: https://www.gastroscan.ru/literature/authors/7752 (дата обращения: 21.02.2023). [Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Barrett's esophagus. Clinical recommendations of the Russian gastroenterological association. 2014. (Electronic resource.) URL: https://www.gastroscan.ru/literature/authors/7752 (access date: 21.02.2023) (in Russ)].
8. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа; 2019. [Maev I.V., Busarova G.A., Andreev D.N. Diseases of the esophagus. M.: GEOTAR-Media, 2019 (in Russ.)].
9. Маев И.В., Самсонов А.А., Белый П.А., Лебедева Е.Г. Гастроэзофагеальная рефлюксная болезнь — лидер кислотозависимой патологии верхних отделов желудочно-кишечного тракта. Consilium Medicum. Гастроэнтерология. 2012;(1):18–24. [Maev I.V., Samsonov A.A., Belyi P.A., Lebedeva E.G. Gastroesophageal reflux disease is the leading acid-dependent pathology of the upper gastrointestinal tract. Consilium Medicum. Gastroenterology. 2012;(1):18–24 (in Russ.)].
10. Cook M.B., Wild C.P., Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050–1061. DOI: 10.1093/aje/kwi325.
11. Thukkani N., Sonnenberg A. The influence of environmental risk factors in hospitalization for gastro-oesophageal reflux disease-related diagnoses in the United States. Aliment Pharmacol Ther. 2010;31(8):852–861. DOI: 10.1111/j.1365-2036.2010.04245.x.
12. Sonnenberg A., Massey B.T., Jacobsen S.J. Hospital discharges resulting from esophagitis among Medicare beneficiaries. Dig Dis Sci. 1994;39(1):183–188. DOI: 10.1007/BF02090080.
13. Richter J.E., Rubenstein J.H. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154(2):267–276. DOI: 10.1053/j.gastro.2017.07.045.
14. Nam S.Y., Choi I.J., Ryu K.H. et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology. 2010;139(6):1902–1911.e2. DOI: 10.1053/j.gastro.2010.08.019.
15. Singh S., Sharma A.N., Murad M.H. et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399–1412.e7. DOI: 10.1016/j.cgh.2013.05.009.
16. Ливзан М.А., Колбина М.В., Матошина И.В. и др. Гормоны жировой ткани и неалкогольная жировая болезнь печени при метаболическом синдроме. Дневник Казанской медицинской школы. 2014;1(4):44–48. [Livzan M.A., Kolbina M.V., Matoshina I.V. Adipose tissue hormones and non-alcoholic fatty liver disease in metabolic syndrome. Kazan medical school diary. 2014;1(4):44–48 (in Russ.)].
17. Abdelkader N.A., Montasser I.F., Bioumy E.E., Saad W.E. Impact of anthropometric measures and serum leptin on severity of gastroesophageal reflux disease. Dis Esophagus. 2015;28(7):691–698. DOI: 10.1111/dote.12271.
18. Nelsen E.M., Kirihara Y., Takahashi N. et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2012;10(7):728–e762. DOI: 10.1016/j.cgh.2012.03.007.
19. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Киселев И.Е. Особенности течения гастроэзофагеальной рефлюксной болезни, ассоциированной с ожирением и избыточной массой тела. Терапевтический архив. 2016;88(2):21–27. [Livzan M.A., Lapteva I., Krolevets T.S., Kiselev I. Specific features of gastroesophageal reflux disease associated with obesity and overweight. Terapevticheskii arkhiv. 2016;88(2):21–27 (in Russ.)]. DOI: 10.17116/terarkh201688221-27.
20. Маев И.В., Юренев Г.Л. Фенотип ожирения и гастроэзофагеальной рефлюксной болезни в контексте коморбидности у больных с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2019;91(2):126–133. [Maev I.V., Yurenev G.L., Mironova E.M., Yureneva-Thorzhevskaya T.V. Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases. Terapevticheskiy arkhiv. 2019;91(2):126–133 (in Russ.)]. DOI: 10.26442/00403660.2019.02.000099.
21. Гаус О.В., Ахмедов В.А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал. 2015;1(124):132–137. [Gaus O.V., Akhmedov V.A. Effect of metabolic syndrome on the state of the liver parenchyma and biliary system in patients with cholelithiasis. Ural medical journal. 2015;1(124):132–137 (in Russ.)].
22. Mikolasevic I., Poropat G., Filipec Kanizaj T. et al. Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. Can J Gastroenterol Hepatol. 2021;2021:6670065. DOI: 10.1155/2021/6670065.
23. Wijarnpreecha K., Panjawatanan P., Thongprayoon C. et al. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: a meta-analysis. Saudi Journal of Gastroenterology. 2017;23(6):311–317. DOI: 10.4103/sjg.sjg_161_17.
24. Hung W.-C., Wu J.-S., Yang Y.-C. et al. Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis. European Journal of Clinical Investigation. 2014;44(12):1143–1149. DOI: 10.1111/eci.12348.
25. Гаус О.В., Ахмедов В.А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник Новосибирского государственного университета. Серия: Биология, клиническая медицина. 2013;11(3):125–129. [Gaus O.V., Akhmedov V.A. Clinical, biochemical and immunological features of cholelithiasis associated with metabolic syndrome. Bulletin of the Novosibirsk State University. Series: Biology, clinical medicine. 2013;11(3):125–129 (in Russ.)].
26. Khan A., Kim A., Sanossian C., Francois F. Impact of obesity treatment on gastroesophageal reflux disease. World J Gastroenterol. 2016;22(4):1627–1638. DOI: 10.3748/wjg.v22.i4.1627.
27. Di Ciaula A., Molina-Molina E., Bonfrate L. et al. Gastrointestinal defects in gallstone and cholecystectomized patients. Eur J Clin Invest. 2019;49(3):e13066. DOI: 10.1111/eci.13066.
28. Кайбышева В.О., Трухманов А.С., Сторонова О.А. и др. Морфофункциональные изменения пищевода при ГЭРБ в зависимости от характера рефлюктата. Клинические перспективы гастроэнтерологии, гепатологии. 2014;5:28–36. [Kaybysheva V.O., Trukhmanov A.S., Storonova О.А. et al. Morphofunctional changes of the esophagus at GERD in relation to refluxate nature. Klinicheskiye perspektivy gastroenterologii, gepatologii. 2014;5:28–36 (in Russ.)].
29. Fass O.Z., Mashimo H. The Effect of Bariatric Surgery and Endoscopic Procedures on Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(1):35–45. DOI: 10.5056/jnm20169.
30. Fox M., Barr C., Nolan S. et al. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5(4):439–444. DOI: 10.1016/j.cgh.2006.12.013.
31. Kahrilas P.J. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70(Suppl 5):S4–S19. DOI: 10.3949/ccjm.70.suppl_5.s4.
32. Savarino V., Marabotto E., Zentilin P. et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol. 2020;13(4):437–449. DOI: 10.1080/17512433.2020.1752664.
33. Pouderoux P., Verdier E., Kahrilas P.J. Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. Am J Physiol Gastrointest Liver Physiol. 2003;284(2):G242-G247. DOI: 10.1152/ajpgi.00301.2002.
34. Бордин Д.С. «Кислотный карман» как патогенетическая основа и терапевтическая мишень при гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2014;2:76–81. [Bordin D.S. "Acid pocket" as a pathogenetic basis and therapeutic target for gastroesophageal reflux disease. Terapevticheskii arkhiv. 2014;2:76–81. (in Russ.)].
35. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;21(4):4–13. [Kaibysheva V.O., Trukhmanov A.S., Ivashkin V.T. Gastroesophageal reflux disease resistant to proton pump inhibitor therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(4):4–13 (in Russ.)].
36. Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16(2):148–156. DOI: 10.5056/jnm.2010.16.2.148.
37. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1943. DOI: 10.1111/j.1572-0241.2006.00630.x.
38. Бордин Д.С., Никольская К.А., Бакулин И.Г. и др. Система поддержки принятия врачебных решений. Гастроэнтерология: Клинические протоколы лечения. М.: ГБУ «НИИОЗММ ДЗМ»; 2021. [Bordin D.S., Nikolskaya K.A., Bakulin I.G. et al. Medical decision support system. Gastroenterology: Clinical treatment protocols. M.: "NIIOZMM"; 2021 (in Russ.)].
39. Алексеенко С.А., Багдасарян А.А., Бакулин И.Г. и др. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Пособие для врачей-терапевтов. Под ред. О.М. Драпкиной. М.: Видокс; 2019. [Alekseyenko S.A., Bagdasaryan A.A., Bakulin I.G., et al. Brief algorithms for managing patients at the stage of providing primary health care. A guide for general practitioners. Drapkina O.M., ed. M.: Vidoks; 2019 (in Russ.)].
40. Gyawali C.P., Kahrilas P.J., Savarino E. et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351–1362. DOI: 10.1136/gutjnl-2017-314722.
41. Yadlapati R., Gyawali C.P., Pandolfino J.E. CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984–994.e1. DOI: 10.1016/j.cgh.2022.01.025.
42. Bischoff S.C., Barazzoni R., Busetto L. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases — Joint ESPEN/UEG guideline. Clin Nutr. 2022;41(10):2364–2405. DOI: 10.1016/j.clnu.2022.07.003.
43. Mathus-Vliegen E.M., Tygat G.N. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–1252. DOI: 10.1080/003655202761020498.
44. Mathus-Vliegen E.M., van Weeren M., van Eerten P.V. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68(2-3):161–168. DOI: 10.1159/000075525.
45. Шептулин А.А., Курбатова А.А., Баранов С.А. Современные возможности применения прокинетиков в лечении больных с гастроэзофагеальной рефлюксной болезнью. Рос журн гастроэнтерол гепатол колопроктол. 2018;28(1):71–77. DOI: 10.22416/1382-4376-2018-28-1-71-77. [Sheptulin A.A., Kurbatova A.A., Baranov S.A. Modern options of prokinetics in gastroesophageal reflux disease treatment. Ross z gastroenterol gepatol koloproktol. 2018;28(1):71–77 (in Russ.)]. DOI: 10.22416/1382-4376-2018-28-1-71-77.
46. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747–757,e350. DOI: 10.1111/j.1365-2982.2012.01888.x.
47. Jung D.H., Huh C.W., Lee S.K. et al. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(2):165–175. DOI: 10.5056/jnm20161.
48. Ezzat W.F., Fawaz S.A., Fathey H., El Demerdash A. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease: prospective study. J Otolaryngol Head Neck Surg. 2011;40(4):350–356.
49. Ливзан М.А., Осипенко М.Ф. Синдром перекреста функциональных заболеваний пищеварительного тракта. РМЖ. 2012;15:768. [Livzan M.A., Osipenko M.F. Syndrome of cross functional diseases of the digestive tract. RMJ. 2012;15:768 (in Russ.)].
50. Sanaka M., Yamamoto T., Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–2440. DOI: 10.1007/s10620-009-1076-x.
51. Kountouras J., Chatzopoulos D., Zavos C. et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002;49(43):193–197.
52. Chun B.J., Lee D.S. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol. 2013;270(4):1385–1390. DOI: 10.1007/s00405-012-2341-8.
53. Ren L.H., Chen W.X., Qian L.J. et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20(9):2412–2419. DOI: 10.3748/wjg.v20.i9.2412.
54. Ndraha S. Combination of PPI with a prokinetic drug in gastroesophageal reflux disease. Acta Med Indones. 2011;43(4):233–236.
55. Miyamoto M., Haruma K., Takeuchi K., Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23(5):746–751. DOI: 10.1111/j.1440-1746.2007.05218.x.
56. Hunt R., Armstrong D., Katelaris P. et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467–478. DOI: 10.1097/MCG.0000000000000854.
57. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H. et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. DOI: 10.14309/ajg.0000000000001538.
58. Iwakiri K., Fujiwara Y., Manabe N. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–285. DOI: 10.1007/s00535-022-01861-z.
59. Jung H.K., Tae C.H., Song K.H. et al. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2021;27(4):453–481. DOI: 10.5056/jnm21077.
60. Gastrooesophageal reflux disease in children and young people: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019.
61. Camilleri M., Atieh J. New Developments in Prokinetic Therapy for Gastric Motility Disorders. Front Pharmacol. 2021;12:711500. DOI: 10.3389/fphar.2021.711500.
62. Goelen N., Jones M., Huang I.H. et al. Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence. United European Gastroenterol J. 2023;11(2):146–162. DOI: 10.1002/ueg2.12362.
63. DiPalma J.R. Metoclopramide: a dopamine receptor antagonist. Am Fam Physician. 1990;41(3):919–924.
64. Bor S., Demir M., Ozdemir O., Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018;6(9):1331–1346. DOI: 10.1177/2050640618799153.
65. Ray W.A., Murray K.T., Meredith S. et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–1096. DOI: 10.1056/NEJMoa040582.
66. Маев И.В., Бордин Д.С., Андреев Д.Н. Тактика врача-гастроэнтеролога: практическое руководство. Под ред. И.В. Маева. М.: ГЭОТАР-Медиа; 2021. [Maev I.V., Bordin D.S., Andreev D.N. Tactics of a gastroenterologist: a practical guide. Maev I.V., ed. Moscow: GEOTAR-Media; 2021 (in Russ.)].
67. Kim Y.S., Kim T.H., Choi C.S. et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol. 2005;11(27):4210–4214. DOI: 10.3748/wjg.v11.i27.4210.
68. Минушкин О.Н., Лощинина Ю.Н. Эффективность применения препарата Ганатон в лечении больных ГЭРБ. Эффективная фармакотерапия в гастроэнтерологии. 2008;3:20–24. [Minushkin O.N., Loschinina Yu.N. Efficacy of Ganaton in GERD therapy. Effective Drug Therapy in Gastroenterology. 2008;3:20–24 (in Russ.)].
69. Takeda N., Takemura M., Kanemitsu Y. et al. Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation. Journal of Asthma. 2019;15:1–9. DOI: 10.1080/02770903.2019.1641204.
70. Huang X., Lv B., Zhang S., Fan Y.H., Meng L.N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371–7377. DOI: 10.3748/wjg.v18.i48.7371.
61. Moayyedi P., Soo S., Deeks J. et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960. DOI: 10.1002/14651858.CD001960.pub3.
72. Pittayanon R., Yuan Y., Bollegala N.P. et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol. 2019;114(2):233–243. DOI: 10.1038/s41395-018-0258-6.
73. Abid S., Jafri W., Zaman M.U. et al. Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia. World J Gastrointest Pharmacol Ther. 2017;8(1):74–80. DOI: 10.4292/wjgpt.v8.i1.74.
74. Holtmann G., Talley N.J., Liebregts T. et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832–840. DOI: 10.1056/NEJMoa052639.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
Распечатать